Loading Events

« All Events

BioNJ’s C-Suite Summit 2022

October 18

A New Era in Life Sciences
With Insights from McKinsey & Company

Register    Sponsor    

Tuesday, October 18, 2022 | Bridgewater Marriott, Bridgewater, NJ*

We have entered a new era in how leaders are shaping the next generation of innovation and Patients are impacting the life sciences industry. With this change comes the opportunity to revolutionize Patient care globally — from new modalities, AI-driven drug discovery and digital therapeutics to a reshuffling of the ecosystem.

Join BioNJ and industry leaders on October 18 to reflect on how the industry might evolve in coming years, identify the catalysts to watch and discuss how to best prepare for (and shape) the next paradigm in life sciences.

7:30 a.m. –
8:15 a.m.
Registration & Networking Breakfast Buffet
8:15 a.m. –
8:30 a.m.
Welcome & Opening Remarks

  • Will Lewis, Chair & CEO, Insmed and Chair, BioNJ
  • Debbie Hart, President & CEO, BioNJ
8:30 a.m. –
9:00 a.m.
Keynote: Decoding the Future of the Life Sciences Industry

A holistic look at how the industry is – and will continue to – evolve, and what this will mean for both incumbents and new entrants. We will look at how the industry has already successfully navigated a period of unprecedented disruption and reflect on how leaders can best prepare for the next wave of change.
  • Rajesh Parekh, Ph.D., Senior Partner, McKinsey & Company
9:00 a.m. –
9:45 a.m.
Panel: Shaping the Change

Industry leaders will discuss the disruptive forces they think are most important to watch, and how to play a role in shaping the future.
  • Greg Hersch, Ph.D., Senior Vice President, Head of Enterprise Strategy, Merck & Co.
  • David Jiménez, President, Janssen Immunology, Janssen Pharmaceutical Companies of Johnson & Johnson
  • Will Lewis, Chair & CEO, Insmed & Chair, BioNJ


  • Greg Graves, Partner, McKinsey & Company 
9:45 a.m. –
10:15 a.m.
Fireside Chat: The Future of Work

Companies across industries are contending with new expectations around talent acquisition, retention and operating models in the wake of the great resignation and a hybrid/remote workforce. This fireside chat will explore how one leader is enhancing their talent value propositions and positioning themselves to lead in the years to come.
Interview with:
  • Maya Martinez-Davis, President, US Pharmaceuticals, GSK
  • Nitin Seth, Chief Executive Officer, Incedo
10:15 a.m. –
10:30 a.m.
Networking Break
10:30 a.m. –
11:15 a.m.
Panel: Markets In Flux

Our panel of experts will discuss how the capital environment for early stage biotechs is evolving, expected sources of growth and how to navigate opportunities for large biopharma, for investors and for early and growth-stage companies.
  • Chris Garabedian, CEO, Xonotogeny and Venture Portfolio Manager, Perceptive Advisors
  • Christopher Mortko, Ph.D., Associate Vice President, Head of HQ Search & Evaluation, Merck Business Development & Licensing
  • Dennis Purcell, Founder, Aisling Capital
  • Monika Vnuk, Managing Director, Blackstone Life Sciences


  • Arda Ural, Ph.D., Americas Industry Markets Leader – Life Sciences & Healthcare, EY
11:15 a.m. –
12:00 p.m.
Panel Discussion: The Clinical Trials Paradigm Shift

Learn how a changing regulatory environment, new consumer expectations and accelerated use of real-world data are fueling an evolution in how new products are developed and launched.
  • Mariah Baltezegar, MBA, Vice President and Head, Peri- and Post-Approval Studies and Real World Evidence Specialized Solutions, PPD (part of Thermo Fisher Scientific)
  • Steven Bulera, Ph.D, Corporate Vice President, Global Head of Toxicology, Charles River Laboratories
  • Terttu Haring, MD, Head, Clinical Innovation Office, Sanofi
  • Paula Rinaldi, Senior Vice President & US Head of Drug Regulatory Affairs, Novartis


  • Jacqueline Berman, Partner, Morgan Lewis
12:00 p.m. –
12:30 p.m.
Fireside Chat: Cell & Gene Therapy – An Opportunity for NJ

CGT is delivering unprecedented efficacy in the biopharma industry. The next wave of innovation will deliver new breadth in diseases reached. Our experts will discuss the opportunity, and its implications for New Jersey as a leading home for the CGT value chain.
Interview with:
  • Audrey Greenberg, Co-Founder & Chief Business Officer, Center for Breakthrough Medicines
  • Robert Hariri, MD, Ph.D., Founder, Chairman & CEO, Celularity
12:30 p.m. –
1:15 p.m.
Networking Lunch
1:15 p.m. –
2:00 p.m.
Panel: The Evolving Market Access Landscape

Experts will discuss how payor-mediated market access continues to play an increasingly important role in determining the success of new product launches and continues to evolve with new utilization management strategies.
  • Bradley Campbell, President & CEO, Amicus Therapeutics
  • Jeff Henderson, Vice President & Head of Global Market Access, Reimbursement and Distribution, Vectiv Bio
  • Dorothy Hoffman, Senior Director, Market Access Policy Team Lead, Pfizer Biopharmaceuticals Group
  • Keith White, Head, Global Market Access, Amylyx
  • Tom Evegan, Principal, Strategy & Management Consulting, RSM
2:00 p.m. –
2:45 p.m.
Panel: Next Generation Patient Experience

The pandemic introduced disruptions to the Patient experience, both delaying care, and at the same time, facilitating an expansion in care access via digital platforms. Against this backdrop, life sciences players will need to continue innovating to enhance the Patient experience, drawing on an array of digital solutions to more holistically engage a diverse customer base.
  • Michael Braun, Senior Vice President, Immunology and Fibrosis at Bristol Myers Squibb
  • Kevin Hagan, President & CEO, PAN Foundation
  • Mary Frances Harmon, Senior Vice President, Corporation Relations, PTC Therapeutics


  • Jim Greenwood, Senior Policy Advisor, Chair, Life Sciences Policy Practice, DLA Piper
2:45 p.m. –
3:00 p.m.
Closing Remarks

  • Debbie Hart, President & CEO, BioNJ
3:00 p.m. –
3:30 p.m.
Networking Reception

BioNJ’s C-Suite Summit will bring together more than 200 life sciences executives representing a wide breadth of companies from early to late stage, public and private and revenue and pre-revenue for a full-day program of timely discussions impacting C-Suite decision-making in bringing new innovative treatments to market. Click here to register. Registration is $695 for Members and $895 for future BioNJ Members. Closed to media.

Contact Cheri Hennessy at CHennessy@BioNJ.org to learn about Sponsorship opportunities. Call (609) 890-3185 with any questions.

*All registrants must be up-to-date on COVID-19 vaccinations as defined by the CDC in order to attend BioNJ’s C-Suite Summit. If the community level of COVID-19 remains low or medium, masks will not be required to be worn, but anyone is welcome to wear a mask based on personal preference. However, if transmission is at a high level, everyone will be required to wear a mask except when eating or drinking. BioNJ will update these protocols, as appropriate, subject to any new CDC guidance or requirements by the venue, in compliance with local/state/federal guidance and we will announce any policy changes in advance of event.


October 18
Event Category: